A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Clinical trial NCT05217355 · COMPLETED
Trial details
- NCT number
- NCT05217355
- Sponsor
- Medytox Korea
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-28
- Primary completion
- 2022-06-22
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.